Vicore Pharma Holding AB
VCRE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.53B
Close$
$2.43
73.2% downside
Current Fair Value
73.2% downsideOvervalued by 73.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.53 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-19.9 |
| Beta | 0.15 |
| Outstanding Shares | 280,086,267 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.56 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$477,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vicore Pharma Holding AB
37 employees
CEO: Ahmed Mousa Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The compa...